Toppy, E. v. Passage Bio, Inc

2022 Pa. Super. 190, 285 A.3d 672
Superior Court of Pennsylvania·Decided November 9, 2022·No. 24 EDA 2021·Published·Cited by 22 cases

Opinion

2022 PA Super 190

ERIC TOPPY IN THE SUPERIOR COURT OF PENNSYLVANIA

Appellant

v.

PASSAGE BIO, INC.

Appellee No. 24 EDA 2021

Appeal from the Order Entered November 25, 2020 In the Court of Common Pleas of Philadelphia County Civil Division at No: 200400905

BEFORE: BOWES, J., STABILE, J., and MUSMANNO, J. OPINION BY STABILE, J.: FILED NOVEMBER 9, 2022 In this employment dispute, Appellant, Eric Toppy, filed a five-count complaint against Appellee, Passage Bio, Inc., alleging that Appellee breached a settlement agreement that resolved Appellant’s wrongful termination claims against Appellee. Appellee filed preliminary objections in the nature of demurrers asserting, inter alia, that the parties never entered a binding settlement agreement. The trial court sustained Appellee’s preliminary objections and dismissed the complaint with prejudice. Appellant appeals from the order of dismissal. We affirm in part and reverse in part. We reverse the dismissal of Appellant’s claims for breach of the settlement agreement and violation of the Wage Payment Collection Law (“WPCL”), 43 P.S. §§ 260.1— 260.13. We affirm the dismissal of Appellant’s claims for unjust enrichment, fraudulent misrepresentation and negligent misrepresentation.

Appellant’s complaint alleges the following. Appellee is an emerging growth company engaged in the development of gene therapies for the treatment of rare central nervous system diseases. In April 2019, based on his prior employment in the health care industry and his relationships with rare disease patient organizations, Appellee hired Appellant as Vice President of Patient Engagement and Market Access. As compensation, Appellee agreed to pay Appellant an annual salary of $260,000 and a bonus targeted at 25% of his base salary. Appellee also granted Appellant 448,623 stock options which were to vest over the ensuing four years.

In October 2019, while Appellant was on a business trip for Appellee in Europe, Appellant’s supervisor, Ms. Quigley, sent Appellant an e-mail stating that she intended to terminate his employment. On his return, Appellant met with Appellee’s general counsel, who told him that his employment was at an end effective October 25, 2019. Having consulted and retained counsel, Appellant then asserted1 three employment-related claims for relief against Appellee: (1) disability discrimination; (2) misrepresentation related to the forfeiture of the 448,623 stock options he had been granted; and (3) defamation related to pejorative comments that Quigley made about him to third parties.

1 Although the complaint is not clear on this point, it appears from context that Appellant first asserted these claims in private correspondence to Appellee as opposed to the filing of a civil action in the court of common pleas.

Appellant and Appellee agreed to mediate his claims before Patricia McInerney, a former common pleas judge. Complaint, ¶¶ 2, 4. On January 30, 2020, the mediation took place. Id. at ¶ 25. The parties reached agreement on two of the three settlement terms that Appellant proposed, namely payment by Appellee of eight months of Appellant’s annual salary and a 25% bonus pro-rated for eight months. Id. at ¶ 26. What remained unresolved was the number of shares of common stock Appellee agreed to issue to Appellant in exchange for his 448,623 stock options.2 Id. at ¶ 27. Settlement negotiations continued over the weekend regarding the number of shares of stock to be issued to Appellant. Id. at ¶ 28. On Monday, February 3, 2020, Appellee agreed to issue Appellant 150,000 shares of common stock. Id.

On February 3, 2020, Judge McInerney sent an e-mail to Appellant’s counsel, Harold Goodman that stated as follows:

I just got out of a meeting and Susan has replied accepting your proposal:

I just heard back from my client. They agree to the terms [Appellant’s counsel] suggested (150,000

2 While stock options “take many forms and have assorted conditions,” Marchlen v. Township of Mt. Lebanon, 746 A.2d 566, 570 n.9 (Pa. 2000), a stock option is, generally speaking, a benefit given by a company to an employee to purchase company stock at a discount or fixed price. Stock shares, on the other hand, represent fractional ownership of an issuing company. Guarantee Trust and Safe Deposit Co. of Mt. Carmel v. Tye, 196 A. 618, 620 (Pa. Super. 1938) (share of stock in business corporation is “one of the whole number of equal parts into which the capital stock of a trading company or corporation is or may be divided”).

shares, 8 months’ severance, 25% bonus pro-rated for 8 months, etc.), with two small tweaks:

1. They want to add Lysogene to the list of companies where [Appellant] cannot work (the others are Axovant and Prevail Therapeutics).

2. Regarding the letter of reference, Steve Squinto is willing to state something like Eric’s role changed and he wanted to leave so that he could continue to work in patient engagement. He does not want to address Eric’s performance as he did not supervise Eric and obviously, Eric’s supervisor was critical of his performance.

They also wanted me to make clear that this is their final position.

Id., ex. 1. Nothing in this email stated or suggested that the stock would be subject to a pre-IPO (initial public offering) reverse stock split. The complaint alleged that the email constituted an agreement because it resolved the final issue between the parties. Id. at ¶ 28 (“Following discussions over the weekend, the parties reached agreement on that remaining issue [the number of shares of common stock]. Specifically, as reflected in the attached Monday, February 3, 2020 e-mail from Judge McInerney, [Appellee] agreed with [Appellant’s] counsel to issue him 150,000 shares of its Common Stock”).

On February 12, 2020, counsel for Appellee sent Appellant’s counsel a draft settlement agreement and release to review. The draft accurately described the severance and bonus payments that Appellant would receive. The draft stated that Appellee would issue Appellant 150,000 shares of its Common Stock, but it added in a vague parenthesis that the number “may be adjusted by stock splits, stock combinations, recapitalizations or the like.” Id.

at ¶ 31. Unbeknownst to Appellant at that time, Appellee already intended to authorize a pre-IPO reverse split3 of its common stock. Id. at ¶ 32. Appellee was aware of this internal decision at the time of the mediation before Judge McInerney (January 30, 2020) and on the day it agreed to issue Appellant 150,000 shares of its common stock (February 3, 2020). Id. at ¶ 33. Despite that, Appellee never said anything to Appellant about the reverse stock split until more than two weeks later. Id. at ¶ 34. On February 18, 2020, counsel for Appellee informed Appellant’s counsel that four days earlier (February 14, 2020), Appellee’s Board of Directors had met and authorized a 4.43316 reverse split of its common stock. Id. No notice of that meeting was sent to Appellant or his counsel. Id. at ¶ 36. In effect, without Appellant’s agreement, Appellee unilaterally decided to reduce the agreed upon shares of common stock to be issued to Appellant from 150,000 to 33,836 shares. Id. at ¶ 34. This occurred after the parties already agreed to issue Appellant 150,000 shares in exchange for his 448,623 stock options, or approximately 33% of the options.

Appellant refused to sign the draft settlement agreement that Appellee sent to Appellant’s counsel on February 12, 2020. Appellee’s Brief at 5.

In an initial public offering on February 28, 2020, Appellee’s stock opened on the NASDAQ Exchange at $18.00 per share. Id. at ¶ 41. Based

3 A reverse stock split is one whereby existing shares of stock are merged to create a smaller number of proportionally more valuable shares. Consequently, the price per share increases proportionally.

Free access — add to your briefcase to read the full text and ask questions with AI

Toppy, E. v. Passage Bio, Inc, 2022 Pa. Super. 190, 285 A.3d 672 (Pa. Ct. App. 2022).

2022 Pa. Super. 190 (Toppy, E. v. Passage Bio, Inc) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Untitled Case
M.D. Pennsylvania, 2026
Petroci, J. v. Chanes, N.
Superior Court of Pennsylvania, 2026
Schnizer, A. v. Crafted Supply Company, LLC
Superior Court of Pennsylvania, 2026
Cobb, A. v. Tesla, Inc.
Superior Court of Pennsylvania, 2026
Fabian, J. v. The Pennsylvania State University
Superior Court of Pennsylvania, 2026
Yaffe, C. v. Gushner, K.
Superior Court of Pennsylvania, 2026
Yaffe, R. v. Gushner, K.
Superior Court of Pennsylvania, 2026
Glass, J. v. Gushner, K.
Superior Court of Pennsylvania, 2026
Green, R. v. John Berg Memorial
Superior Court of Pennsylvania, 2025
Klimenko, A. v. Denaburg, D.
Superior Court of Pennsylvania, 2025
Toppy, E. v. Passage Bio
Superior Court of Pennsylvania, 2025
GNS Enterprises v. AMA Ridge, LLC
Superior Court of Pennsylvania, 2025
Giordano, M. V. Ashfield Healthcare
Superior Court of Pennsylvania, 2025
KNUEVEN v. LYSTEN, LLC
E.D. Pennsylvania, 2025
Durst, R. v. Marom Gerritt, II, L.P.
Superior Court of Pennsylvania, 2025
Eric Daimler v. Chris Moehle
Third Circuit, 2025